Basilea Pharmaceutica Ltd. reported today that detailed efficacy and safety data of the isavuconazole invasive aspergillosis study were presented at the European Congress of Clinical Microbiology and Infectious Diseases in Barcelona, Spain.
http://ift.tt/1jg837C
http://ift.tt/1jg837C
No comments:
Post a Comment